Thursday, January 20, 2022

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview

 Lexaria Bioscience (NASDAQ: LEXX) CEO and chair Chris Bunka is the guest on a recent episode of the EDGE podcast. Hosted by entrepreneur and angel investor Brandon C. White, the EDGE is a podcast series focused on providing a playbook for business owners that takes a look at the inner game of building a successful business and giving listeners the edge to become smarter, healthier and richer. Lexaria Bioscience is a global innovator in drug-delivery platforms. During the interview, Bunka shared his background and the journey that led him to Lexaria. He also talked about Lexaria’s business model and the company’s focus on improving the delivery of active pharmaceutical ingredients, vitamins and minerals. In addition, he discussed Lexaria’s ongoing efforts to leverage its innovative drug-delivery platform to improve the effectiveness of orally delivered compounds. “Lexaria Bioscience is a tech company, and we provide really, really interesting solutions to the pharmaceutical industry, as well as nutraceuticals and even delivery of beneficial vitamins and minerals in foods,” said Lexaria Bioscience CEO and chair Chris Bunka in the podcast. “Our technology is all about enabling a much higher fraction and a much smoother delivery of the beneficial substances in the foods you eat and in the drugs you take and, quite frankly, getting them into your bloodstream. With a lot of these compounds and drugs, the vast majority of what you eat or swallow ends up in the toilet, and that’s no good. So we can fix that.”

To view the full interview, visit https://ibn.fm/153ow 

To view the full press release, visit https://ibn.fm/9qTYO

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by 5 to 10 times as well as reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs; nonsteroidal, anti-inflammatory drugs (“NSAIDs”); and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html